Friday, October 16, 2020 1:43:55 PM
RLF raised $30M+ from the 400M shares to GEM recently, to continue Trials and start operations after the 'partnership' with NRX. It's only $400k for the VIP (their price obviously less) drugs and then administering it.
Nel, there are Plenty of patients now to complete enrollments. They deserve treatments. Cant figure why you say April for data/Trial completion except that they aren't enrolling anymore.?. Also cant figure why they're stopping at 102 in the phase 2b of the 2b/3 IV Trial. Sure great data, BUT. Look at the FIELD of companies going thru the process and the MANY different approaches being tested and their value Proven or Not, ALL thru full normal Clinical Trials' progression.
I dont count on inside help (Harris?) at the FDA, especially whit the current state of political confusions they are dealind with. All JMHO.
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM